Tempest Announces Data Presentations, including a Late-Breaking Presentation on TPST-1120, at the SITC Annual Meeting
November 02 2022 - 7:00AM
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage
oncology company developing first-in-class1 therapeutics that
combine both targeted and immune-mediated mechanisms, today
announced the acceptance of two poster presentations, including a
late-breaking presentation on the company’s oral selective PPAR⍺
antagonist, TPST-1120, at the Society for Immunotherapy of Cancer
(SITC) 37th Annual Meeting taking place November 10-12, 2022 in
Boston, MA.
Late-breaking poster presentation details:
Title: |
|
Pharmacodynamic and predictive biomarkers associated with response
in cancer patients treated with TPST-1120: a first-in-class, small
molecule antagonist of Peroxisome-Proliferator Activated
Receptor-Alpha |
Abstract #: |
|
1471 |
Date: |
|
Thursday, November 10, 2022 |
Time: |
|
9:00 a.m. – 9:00 p.m. ET |
Location: |
|
Poster Hall C |
Poster presentation details:
Title: |
|
Dual Blockade of the EP2 and EP4 PGE2 Receptors with TPST-1495 is
an Optimal Approach for Drugging the Prostaglandin Pathway |
Abstract #: |
|
1331 |
Date: |
|
Thursday, November 10, 2022 |
Time: |
|
9:00 a.m. – 9:00 p.m. ET |
Location: |
|
Poster Hall C |
Full abstracts will be available for viewing
starting on Monday, November 7, 2022 at 8:00 a.m. ET in the Journal
for ImmunoTherapy of Cancer (JITC) supplement found at
https://jitc.bmj.com/.
——————————————
1 If approved by the FDA
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage
oncology company advancing small molecules that combine both
tumor-targeted and immune-mediated mechanisms with the potential to
treat a wide range of tumors. The company’s two novel clinical
programs are TPST-1120 and TPST-1495, antagonists of PPARα and
EP2/EP4, respectively. Both programs are advancing through clinical
trials designed to study the agents as monotherapies and in
combination with other approved agents. Tempest is also developing
an orally available inhibitor of TREX1, a target that controls
activation of the cGAS/STING pathway. Tempest is headquartered in
South San Francisco. More information about Tempest can be found on
the company’s website at www.tempesttx.com.
Investor Contacts:Sylvia WheelerWheelhouse Life
Science Advisorsswheeler@wheelhouselsa.com
Aljanae Reynolds Wheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From Jul 2024 to Jul 2024
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From Jul 2023 to Jul 2024